Epithelial Tumor clinical trials at UC Cancer
3 research studies open to eligible people
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
open to eligible people ages 18 years and up
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
at UCLA
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
open to eligible people ages 18 years and up
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.
at UCLA
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
open to eligible people ages 18 years and up
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours. To characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or advanced epithelial tumours
at UCLA
Our lead scientists for Epithelial Tumor research studies include Lee Rosen, MD.
Last updated: